Monograph Details
|
|
Hematology
> Anemias
|
|
DROXIA |
| Manufacturer |
|
Bristol-Myers Squibb |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Substituted urea. |
| Generic Name |
|
Hydroxyurea 200mg, 300mg, 400mg; caps. |
| Indications |
|
To reduce the frequency of painful crises and to reduce the need for blood transfusions in adults with sickle cell anemia with recurrent moderate-to-severe painful crises. |
| Children |
|
Not recommended. |
| Adults |
|
Base dose on ideal or actual weight, whichever is less. Initially 15mg/kg/day as a single dose. May increase dose by 5mg/kg/day every 12 weeks to maximum tolerated dose or 35mg/kg/day achieved; do not increase dose if blood counts are between acceptable range and toxic. If blood counts toxic, discontinue until hematologic recovery, see literature for dosage adjustments. Renal impairment (CrCl <60mL/min or ESRD): initially 7.5mg/kg per day; give dose following dialysis. |
| Precautions |
|
Markedly depressed bone marrow function: not recommended. Monitor hematologic, renal, and liver function before and during therapy. Renal dysfunction. Macrocytosis may mask folic acid deficiency; prophylactic folic acid is recommended. Pregnancy (Cat.D); avoid use. Nursing mother: not recommended. |
| Interactions |
|
Avoid concomitant didanosine, with or without stavudine, other antiretrovirals (may cause pancreatitis, fatal hepatotoxicity, peripheral neuropathy). Concomitant interferon: increased risk of vasculitic toxicities; discontinue hydroxyurea if cutaneous vasculitis ulcerations develop. |
| Adverse Reactions |
|
Neutropenia, thrombocytopenia, low reticulocyte count, hair loss, rash, fever, GI upset, weight gain, bleeding, parvovirus B-19 infection, melanonychia, erythema, CNS effects, temporary renal impairment, acute pulmonary reactions, secondary leukemias. |
| Extra Text |
|
Note: Wear disposable gloves when handling caps or bottle. |
| How Supplied |
|
Caps—60 |
|
|
|
|
